OTCMKTS:KHTRF Knight Therapeutics - KHTRF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.47 0.00 (0.00%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.47▼$3.4750-Day Range$3.47▼$3.9652-Week Range$3.47▼$4.77VolumeN/AAverage Volume2,388 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.08 ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest Knight Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside75.1% Upside$6.08 Price TargetShort InterestBearishDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.22 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $6.08, Knight Therapeutics has a forecasted upside of 75.1% from its current price of $3.47.Amount of Analyst CoverageKnight Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverKnight Therapeutics has a short interest ratio ("days to cover") of 53.5, which indicates bearish sentiment.Change versus previous monthShort interest in Knight Therapeutics has recently decreased by 22.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KHTRF. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Knight Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Knight Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 24.85% of the stock of Knight Therapeutics is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About Knight Therapeutics (OTCMKTS:KHTRF) StockKnight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.Read More Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KHTRF Stock News HeadlinesMarch 26, 2023 | markets.businessinsider.comBloom Burton Keeps Their Buy Rating on Knight Therapeutics (KHTRF)March 24, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Knight Therapeutics (KHTRF)March 28, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 24, 2023 | finance.yahoo.comG2S2 CAPITAL INC. ANNOUNCES INVESTMENT IN KNIGHT THERAPEUTICS INC.March 23, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Knight Therapeutics (KHTRF)January 26, 2023 | finance.yahoo.comBerkadia Forges Alliance With Knight FrankDecember 23, 2022 | marketwatch.comKnight Therapeutics Closes $38.5 Mln Loan With International Finance Corp.December 23, 2022 | finance.yahoo.comKnight Therapeutics Closes US$38.5 million Loan with IFCMarch 28, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureNovember 13, 2022 | seekingalpha.comKnight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Call TranscriptNovember 12, 2022 | finance.yahoo.comKnight Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsNovember 9, 2022 | finance.yahoo.comKnight to Present at Stifel Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comNotice of Knight Therapeutics' Third Quarter 2022 Results Conference CallAugust 12, 2022 | seekingalpha.comKnight Therapeutics' (KHTRF) CEO Samira Sakhia on Q2 2022 Results - Earnings Call TranscriptAugust 12, 2022 | benzinga.comG2S2 CAPITAL INC. FILES EARLY WARNING REPORT FOR INVESTMENT IN KNIGHT THERAPEUTICS INC.July 4, 2022 | nasdaq.comKnight Therapeutics To Relaunch AKYNZEO In BrazilJune 14, 2022 | finance.yahoo.comDoes Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?May 24, 2022 | seekingalpha.comKnight Therapeutics enters license, supply pacts with RigelMay 12, 2022 | finance.yahoo.comKnight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®March 31, 2022 | finance.yahoo.comKnight Therapeutics Inc. (TSE:GUD) insiders placed bullish bets worth CA$3.1m in the last 12 monthsMarch 25, 2022 | seekingalpha.comKnight Therapeutics reports Q4 resultsMarch 17, 2022 | finance.yahoo.comNotice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference CallJanuary 7, 2022 | nasdaq.comKnight Therapeutics Inc (KHTRF)December 14, 2021 | finance.yahoo.comIs Knight Therapeutics (TSE:GUD) Using Too Much Debt?December 2, 2021 | finance.yahoo.comKnight to Present at Stifel GMP’s The Future of Healthcare ConferenceNovember 11, 2021 | finance.yahoo.comKnight Therapeutics Reports Third Quarter 2021September 30, 2021 | finance.yahoo.comWhat Type Of Shareholders Make Up Knight Therapeutics Inc.'s (TSE:GUD) Share Registry?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KHTRF Company Calendar Today3/28/2023Next Earnings (Estimated)5/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:KHTRF CUSIPN/A CIKN/A Webwww.gud-knight.com Phone(514) 484-4483FaxN/AEmployees660Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.08 High Stock Price Forecast$6.75 Low Stock Price Forecast$5.40 Forecasted Upside/Downside+75.1%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesSamira SakhiaPresident, Chief Executive Officer & DirectorUtchanah ArvindChief Financial OfficerMonica PercarioVice President-Global Scientific AffairsDaniela Marino MarinoVice President-Legal and ComplianceAmal KhouriChief Business OfficerKey Competitors1933 IndustriesOTCMKTS:TGIFF4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFAcreageOTCMKTS:ACRHFView All Competitors KHTRF Stock - Frequently Asked Questions What is Knight Therapeutics' stock price forecast for 2023? 0 Wall Street analysts have issued 12 month price targets for Knight Therapeutics' shares. Their KHTRF share price forecasts range from $5.40 to $6.75. On average, they predict the company's stock price to reach $6.08 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts. How have KHTRF shares performed in 2023? Knight Therapeutics' stock was trading at $3.80 at the start of the year. Since then, KHTRF shares have decreased by 8.7% and is now trading at $3.47. View the best growth stocks for 2023 here. Are investors shorting Knight Therapeutics? Knight Therapeutics saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 123,500 shares, a decrease of 5.6% from the February 13th total of 130,800 shares. Based on an average daily trading volume, of 6,300 shares, the short-interest ratio is presently 19.6 days. View Knight Therapeutics' Short Interest. When is Knight Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our KHTRF earnings forecast. What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF." How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Knight Therapeutics' stock price today? One share of KHTRF stock can currently be purchased for approximately $3.47. How many employees does Knight Therapeutics have? The company employs 660 workers across the globe. How can I contact Knight Therapeutics? Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483. This page (OTCMKTS:KHTRF) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.